- Mithra Pharmaceuticals SA sells all shares held in Neuralis SA and Estetra SRL as well as specific assets of Mithra R&D SA to Gedeon Richter for an aggregate price of EUR 175 million. This transaction was signed and completed on 11 June 2024
- Mithra CDMO and Novalon SA remain under court protection and are therefore not affected by the transaction announced today
Liège, Belgium, 11 June 2024 – 18:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, under bankruptcy, today announces that it is selling Gedeon Richter all shares in Neuralis SA and Estetra SRL held by Mithra Pharmaceuticals SA and specific assets held by Mithra R&D SA relating to the manufacture of estetrol. This means the entire business related to the research, development, manufacturing, marketing and post-marketing scientific work relating to estetrol is transferred to Gedeon Richter. Signing and completion of this transaction took place on 11 June 2024.
This transfer includes the related intellectual property rights and current contracts, as well as ESTELLE® (already marketed) and DONESTA® (in development). Gedeon Richter will be responsible for submitting the DONESTA® filing to the agencies and for liaising with the regulatory agencies for the purposes of obtaining marketing authorization and then marketing the product via existing and future contracts.
The Mithra CDMO and Novalon SA entities are not affected by the sale announced today as they are subject to separate judicial reorganization proceedings. The judicial protection measures to which they are subject should, subject to the court’s approval, be extended until 30 June 2024. This extension is intended to allow the different parties interested in Mithra CMDO’s assets to continue their due diligence and submit binding offers by mid-month.
From an employment point of view, all 49 members of the personnel engaged by the transferred entities will be able to pursue their activities with Gedeon Richter. In addition, 17 other people of Mithra Pharmaceuticals SA have also been offered to join the transferred entities and thus work for Gedeon Richter.
The sale of Neuralis SA and Estetra SRL as well as certain assets of Mithra R&D SA to Gedeon Richter is valued for a total consideration of EUR 175 million. The amount received, after deduction of financial debts, will be used to repay certain amounts to Mithra’s creditors in the order of their legal privilege. As a result, this transaction does not create any value for the shareholders of Mithra Pharmaceuticals SA.